Market Closed -
London S.E.
11:35:14 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
32.95
GBX
|
-5.45%
|
|
-7.31%
|
+29.22%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
12.58
|
28.4
|
37.46
|
112.9
|
147.5
|
105.1
|
105.1
|
-
|
Enterprise Value (EV)
1 |
12.58
|
28.4
|
36.44
|
102.5
|
143.5
|
69.14
|
102.1
|
99.06
|
P/E ratio
|
-
|
-
|
-15.4
x
|
-21.5
x
|
-25.2
x
|
-
|
-34.2
x
|
42
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
894
x
|
-
|
-
|
-
|
24.8
x
|
11
x
|
6.39
x
|
EV / Revenue
|
-
|
894
x
|
-
|
-
|
-
|
22.3
x
|
10.7
x
|
6.03
x
|
EV / EBITDA
|
-
|
-
|
-12,550,676
x
|
-17,528,053
x
|
-20,952,058
x
|
-
|
-99,622,481
x
|
25,012,052
x
|
EV / FCF
|
-
|
-
|
-8.01
x
|
-23.9
x
|
-22
x
|
-73.9
x
|
-22.7
x
|
26.8
x
|
FCF Yield
|
-
|
-
|
-12.5%
|
-4.19%
|
-4.54%
|
-1.35%
|
-4.4%
|
3.73%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
204,583
|
204,660
|
245,627
|
287,151
|
288,047
|
301,449
|
301,449
|
-
|
Reference price
2 |
0.0615
|
0.1388
|
0.1525
|
0.3930
|
0.5120
|
0.3485
|
0.3485
|
0.3485
|
Announcement Date
|
4/10/19
|
4/1/20
|
4/14/21
|
4/26/22
|
4/5/23
|
4/10/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
0.0318
|
-
|
-
|
-
|
3.101
|
9.518
|
16.43
|
EBITDA
|
-
|
-
|
-2.903
|
-5.846
|
-6.847
|
-
|
-1.025
|
3.96
|
EBIT
1 |
-
|
-
|
-2.928
|
-5.866
|
-6.871
|
-6.964
|
-3.128
|
2.226
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-224.57%
|
-32.86%
|
13.55%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-2.927
|
-5.866
|
-6.871
|
-6.892
|
-2.796
|
2.339
|
Net income
|
-5.881
|
-
|
-2.408
|
-4.958
|
-5.846
|
-
|
-3.072
|
2.497
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-32.28%
|
15.2%
|
EPS
|
-
|
-
|
-0.009900
|
-0.0183
|
-0.0203
|
-
|
-0.0102
|
0.008300
|
Free Cash Flow
1 |
-
|
-
|
-4.552
|
-4.293
|
-6.516
|
-0.9356
|
-4.498
|
3.695
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-30.17%
|
-47.26%
|
22.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
93.3%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
147.99%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/10/19
|
4/1/20
|
4/14/21
|
4/26/22
|
4/5/23
|
4/10/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
1.02
|
10.4
|
4.03
|
7.71
|
2.94
|
5.99
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-4.55
|
-4.29
|
-6.52
|
-0.94
|
-4.5
|
3.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.01
|
0.42
|
0.74
|
-
|
1.98
|
0.49
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
20.79%
|
2.99%
|
Announcement Date
|
4/10/19
|
4/1/20
|
4/14/21
|
4/26/22
|
4/5/23
|
4/10/24
|
-
|
-
|
Last Close Price
0.3485
GBP Average target price
1.263
GBP Spread / Average Target +262.51% Consensus |
1st Jan change
|
Capi.
|
---|
| +29.22% | 132M | | -3.22% | 102B | | +1.59% | 96.29B | | +2.13% | 22.18B | | -15.74% | 21.2B | | -9.21% | 18.31B | | -39.98% | 17.38B | | -14.83% | 16.36B | | +5.32% | 13.97B | | +33.88% | 12.17B |
Bio Therapeutic Drugs
|